Literature DB >> 3143723

Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.

H R Lijnen1, L Nelles, B Van Hoef, E Demarsin, D Collen.   

Abstract

A chimeric plasminogen activator (t-PA/scu-PA-s), consisting of amino acids 1-263 of tissue-type plasminogen activator (t-PA) and 144-411 of single-chain urokinase-type plasminogen activator (scu-PA), was previously shown to maintain the enzymatic properties of scu-PA but to have only partially acquired the fibrin affinity of t-PA, possibly as a result of steric interaction between the functional domains of t-PA and scu-PA (Nelles, L., Lijnen, H. R., Collen, D., and Holmes, W.E. (1987) J. Biol. Chem. 262, 10855-10862). Therefore, we now have constructed an extended chimeric t-PA/scu-PA protein, consisting of amino acids 1-274 of t-PA and 138-411 of scu-PA, which thus has an additional sequence of 17 residues in the region joining the two proteins. The highly purified extended chimeric protein (t-PA/scu-PA-e) was found to have similar specific activity on fibrin film (65,000 IU/mg), kinetic constants for the activation of plasminogen (Km = 1 microM, k2 = 0.0026 s-1), fibrin affinity (50% binding at a fibrin concentration of 3.3 g/liter), and fibrin specificity of clot lysis in a plasma environment (50% lysis in 2 h with 8 nM of the chimer) as the previously characterized chimeric protein (t-PA/scu-PA-s). Thus, unexpectedly, the fibrin affinity of t-PA is also only partially expressed in this extended chimeric protein. Therefore, the NH2-terminal chains (A-chains) of the plasmin-generated two-chain derivatives t-PA/tcu-PA-e, t-PA/tcu-PA-s, and of t-PA were isolated. These A-chain structures of the chimers were found to have lost most of their fibrin affinity, whereas the fibrin affinity of the A-chain of native t-PA was maintained. Differential reactivity of the A-chain structures of both chimeric molecules with monoclonal antibodies directed against the A-chain of t-PA suggested that they were conformationally altered. Sequential fibrin binding experiments with t-PA/scu-PA-e and t-PA/scu-PA-s yielded 45 +/- 8 (n = 11) and 43 +/- 5% (n = 8), respectively, binding in the first cycle and 44 +/- 7 (n = 11) and 27 +/- 10% (n = 8), respectively, binding in the second cycle. This suggests that the low affinity of the chimeric molecules for fibrin is not due to the occurrence of subpopulations of molecules with different fibrin affinity but, instead, to a uniformly decreased fibrin affinity in all molecules.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143723

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

Review 1.  Thrombolysis. An approach still on the move.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

2.  Chinese hamster ovary cells continuously secrete a cysteine endopeptidase.

Authors:  M Satoh; S Hosoi; S Sato
Journal:  In Vitro Cell Dev Biol       Date:  1990-11

Review 3.  Novel thrombolytic agents.

Authors:  M Verstraete; H R Lijnen
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

Review 4.  Tissue plasminogen activator for thrombolytic therapy: expectation versus reality.

Authors:  P J Gaffney
Journal:  J R Soc Med       Date:  1992-11       Impact factor: 18.000

5.  Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue.

Authors:  Ivana Zagotta; Elitsa Y Dimova; Jan-Bernd Funcke; Martin Wabitsch; Thomas Kietzmann; Pamela Fischer-Posovszky
Journal:  Oxid Med Cell Longev       Date:  2013-06-02       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.